Ruboxistaurin 32 mg daily for 8 weeks did not significantly alter renal hemodynamic function compared to placebo during clamped euglycemia or hyperglycemia in patients with type 1 diabetes.
RCT (n=20)
2:1
Does ruboxistaurin improve renal hemodynamic function and urinary biomarkers in albuminuric subjects with type 1 diabetes on renin angiotensin system blockade?
In a pilot study of type 1 diabetics on RAS blockade, ruboxistaurin did not significantly alter renal hemodynamics overall, though post hoc analyses suggest modest effects dependent on baseline GFR and glycemia.
OBJECTIVE: The aim of this study was to examine the effect of protein kinase Cbeta inhibition with ruboxistaurin on renal hemodynamic function and urinary biomarkers (monocyte chemoattractant protein-1 MCP-1 and epidermal growth factor) in renin angiotensin system blockade-treated type 1 diabetic subjects. RESEARCH DESIGN AND METHODS: Albuminuric subjects were randomized (2:1) to ruboxistaurin (32 mg daily; n = 13) or placebo (n = 7) for 8 weeks. Renal hemodynamic function was measured during clamped euglycemia or hyperglycemia and before and after ruboxistaurin or placebo. RESULTS: Ruboxistaurin was not associated with between-group differences during clamped euglycemia or hyperglycemia. In a post hoc analysis comparing hyperfilterers with normofilterers during euglycemia, glomerular filtration rate and MCP-1 decreased, whereas the epidermal growth factor-to-MCP-1 ratio increased in hyperfilterers versus normofilterers (all P < 0.05). CONCLUSIONS: The effect of ruboxistaurin is modest and dependent, at least in part, on the level of ambient glycemia and baseline glomerular filtration rate.
Cherney et al. (2008) conducted an RCT in Type 1 diabetes with albuminuria (n=20). Ruboxistaurin vs. Placebo was evaluated on Renal hemodynamic function and urinary biomarkers (MCP-1 and epidermal growth factor). Ruboxistaurin 32 mg daily for 8 weeks did not significantly alter renal hemodynamic function compared to placebo during clamped euglycemia or hyperglycemia in patients with type 1 diabetes.